Chapter 8: Antimicrobial Therapy Flashcards
In patients being treated with parenteral antibiotic, when is switching to oral indicated
Patient is responding to therapy, patient can take oral medications and absorb them, an oral equivalent is available
Endocarditis most likely organism/s
Staph aureus
Intrabdominal tissue most likely organism/s
E Coli, enterococcus, anaerobes, negative aerobic bacilli
Meningitis <2 months most likely organism/s
E coli, Group B strep, listeria
Meningitis 2 month-12 years most likely organism/s
Strep pneumoniae, N. meningitidis, H. Influenzae
Meningitis adult most likely organism/s
Strep pneumoniae, N. meningitidis
Upper respiratory tract most likely organism/s
S. Pneumoniae, H. Influenzae, moreaxella catarrhalis, Group A strep
Lower respiratory tract most likely organism/s
S. Pneumoniae, H. Influenzae, M. Catarrhalis, Klebsiella pneumoniae, mycoplasma pneumoniae, c. pneumoniae, viruses
Aspiration pneumonia most likely organism/s
Mouth flora
Lower tract hospital acquired most likely organism/s
S. Aureus, pseudomonas, other G- aerobic bacilli
Respiratory tract HIV coinfected most likely organism/s
Pneumocystis, S. Pneumoniae
Diabetic ulcer most likely organism/s
Staph, Strep, G- aerobic bacilli, anaerobes
UTI community most likely organism/s
E coli, enterococcus, staph saprophyticus
UTI hospital
E coli, enterococcus
Penicilin MOA
Bactericidal
Interferes with cell wall synthesis
Inactivates protein binding proteins
Penicilin active against
Staph, strep, most enterococcus
No activity against MRSA
DOC G+ infections such as endocarditis
Beta lactamase inhibitors
Clavulanic acid, avibactam, sulbactam, tazobactam
Use of beta lactam/beta lactamase inhibitors
intraabdominal and gynecological and skin/soft tissue infections, aspiration pneumonia, sinusitis, lung abscesses
Beta lactam/lactamase inhibitors are incompatible with
Aminoglycosides
Cephalosporins MOA
Bactericidal
Cell wall synthesis inhibition
Progression from 1st to 4th generation cephalosporins
Reflects an increase in G- coverage and loss of G+ activity
3rd and 4th cephalosporins can penetrate
CSF
Can treat meningitis
1st generation cephalosporins can treat
G+ skin infections, pneumoccoal respiratory, UTI, surgical prophylaxis
2nd generation cephalosporins treat
Community acquired pneumonia, other respiratory and skin infections
Monobactam agent
Aztreonam
Inhibits cell wall synthesis
Bactericidal
Aztreonam is active against
G-, including pseudomonas
Aztreonam to treat
Complicated and uncomplicated UTI and respiratory tract infections (pneumonia and bronchitis)
Carbapenems
Bactericidal Most broad spectrum agents available Not absorbed orally widely distributed with some CSF penetration Inhibit cell wall synthesis
Most broad spectrum carbapenems
Imipenem, meropenem, doripenem
Carbapenems useful in treating
Polymicrobial infections; skin and soft tissue, bone and joint, intrabdominal and lower respiratory tract
What can decrease clearance of meropenem and doripenem
Probenecid
Fluoroquinolones
-Floxacin
Bactericidal
Inhibits DNA gyrase and topoisomerase IV
Fluoroquinolones have activity against
G- aerobic bacteria and some G+
Only oral flouroquinolones active against pseudomonas
Ciproflaxacin and levofloxacin